We assessed AYA22T-aptamers’ binding specificity to NKG2A on NK cells, aiming to enhance NK cell-mediated tumor lysis by disrupting NKG2A interactions with the HLA-E axis. This evidence concerns the gene KLRC1 and neoplasm.